Moreover, concerns have recently been raised regarding the infection-related safety profile of sodium-glucose co-transporter 2 (SGLT2) inhibitors, which are a relatively novel class of glucose-lowering agents for treating T2D. Here, SLC5A2 is linked to type 2 diabetes mellitus.